Benzinga | Oct 13, 2020 08:26AM EDT

Morgan Stanley Maintains Overweight on BeiGene, Raises Price Target to $270

Morgan Stanley maintains BeiGene (NASDAQ:BGNE) with a Overweight and raises the price target from $241 to $270.